Faisal Khurshid
Stock Analyst at Jefferies
(4.72)
# 158
Out of 5,239 analysts
41
Total ratings
62.5%
Success rate
50.98%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Assumes: Buy | $48 → $40 | $21.38 | +87.09% | 1 | Mar 30, 2026 | |
| FDMT 4D Molecular Therapeutics | Assumes: Buy | $40 → $21 | $10.79 | +94.62% | 1 | Mar 30, 2026 | |
| PTCT PTC Therapeutics | Downgrades: Hold | $91 → $76 | $76.85 | -1.11% | 1 | Mar 30, 2026 | |
| VSTM Verastem | Assumes: Buy | $19 → $15 | $4.88 | +207.38% | 1 | Mar 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $107 → $110 | $103.50 | +6.28% | 2 | Mar 19, 2026 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $122 → $110 | $84.10 | +30.80% | 4 | Mar 16, 2026 | |
| INSM Insmed | Assumes: Buy | $228 | $103.89 | +119.46% | 1 | Mar 16, 2026 | |
| COGT Cogent Biosciences | Assumes: Buy | $55 | $34.10 | +61.29% | 1 | Mar 16, 2026 | |
| DSGN Design Therapeutics | Initiates: Buy | $15 | $15.61 | -3.91% | 1 | Mar 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $160 | $122.13 | +31.01% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $420 → $290 | $310.75 | -6.68% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $522 → $330 | $284.84 | +15.85% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $94 | $100.32 | -6.30% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $16 | $14.88 | +7.53% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $4 | $5.25 | -23.81% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $13.65 | +46.52% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $0.95 | +5.24% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $7.02 | -71.51% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $102 | $87.39 | +16.72% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $1 | $4.17 | -76.02% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $76.43 | -41.12% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $16.28 | -1.72% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.20 | +66.67% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $78.71 | +1.64% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $4.75 | +215.79% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.45 | +157.88% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.39 | +403.60% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.36 | +138.10% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $50 | $12.00 | +316.67% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $1.46 | +653.42% | 1 | Mar 21, 2023 |
Syndax Pharmaceuticals
Mar 30, 2026
Assumes: Buy
Price Target: $48 → $40
Current: $21.38
Upside: +87.09%
4D Molecular Therapeutics
Mar 30, 2026
Assumes: Buy
Price Target: $40 → $21
Current: $10.79
Upside: +94.62%
PTC Therapeutics
Mar 30, 2026
Downgrades: Hold
Price Target: $91 → $76
Current: $76.85
Upside: -1.11%
Verastem
Mar 30, 2026
Assumes: Buy
Price Target: $19 → $15
Current: $4.88
Upside: +207.38%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $107 → $110
Current: $103.50
Upside: +6.28%
Kymera Therapeutics
Mar 16, 2026
Assumes: Buy
Price Target: $122 → $110
Current: $84.10
Upside: +30.80%
Insmed
Mar 16, 2026
Assumes: Buy
Price Target: $228
Current: $103.89
Upside: +119.46%
Cogent Biosciences
Mar 16, 2026
Assumes: Buy
Price Target: $55
Current: $34.10
Upside: +61.29%
Design Therapeutics
Mar 16, 2026
Initiates: Buy
Price Target: $15
Current: $15.61
Upside: -3.91%
ABIVAX Société Anonyme
Mar 16, 2026
Initiates: Buy
Price Target: $160
Current: $122.13
Upside: +31.01%
Mar 16, 2026
Downgrades: Hold
Price Target: $420 → $290
Current: $310.75
Upside: -6.68%
Mar 16, 2026
Downgrades: Hold
Price Target: $522 → $330
Current: $284.84
Upside: +15.85%
Mar 16, 2026
Downgrades: Hold
Price Target: $120 → $94
Current: $100.32
Upside: -6.30%
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $14.88
Upside: +7.53%
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $5.25
Upside: -23.81%
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $13.65
Upside: +46.52%
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.95
Upside: +5.24%
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $7.02
Upside: -71.51%
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $87.39
Upside: +16.72%
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $4.17
Upside: -76.02%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $76.43
Upside: -41.12%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $16.28
Upside: -1.72%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.20
Upside: +66.67%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $78.71
Upside: +1.64%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $4.75
Upside: +215.79%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.45
Upside: +157.88%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.39
Upside: +403.60%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.36
Upside: +138.10%
Sep 9, 2024
Assumes: Outperform
Price Target: $50
Current: $12.00
Upside: +316.67%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $1.46
Upside: +653.42%